Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

10.63 

0.15 1.4%

as of Mar 30 '23

52 Week Range:

10.34 27.30


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20 Dec '20 Dec '21
Equity (BVPS) 6.35
6.33
7.20
8.66
10.02
9.56
11.62
12.94
11.51
10.66
growth rate -0.3% 13.7% 20.3% 15.7% -4.6% 21.6% 11.4% -11.1% -3.8%
Earnings BIT 274.40
134.20
153.40
43.20
60.70
7.60
-132.00
-194.80
-126.70
growth rate -51.1% 14.3% -71.8% 40.5% -87.5% -100.0% 0.0% 0.0%
Avg.PE 19.68
87.37
14.59
14.59
14.59
14.59
14.59
growth rate 344.0% -83.3% 0.0% 0.0% 0.0% 0.0%
ROA 17.23
19.69
21.65
10.09
15.22
2.07
10.93
0.34
-13.45
-1.99
growth rate 14.3% 10.0% -53.4% 50.8% -86.4% 428.0% -96.9% -100.0% 0.0%
ROE 18.65
21.57
24.35
11.61
17.77
2.86
15.04
0.45
-19.88
-2.94
growth rate 15.7% 12.9% -52.3% 53.1% -83.9% 425.9% -97.0% -100.0% 0.0%
ROIC 18.18
21.06
23.88
11.58
17.68
2.86
14.29
1.17
-15.11
-2.05
growth rate 15.8% 13.4% -51.5% 52.7% -83.8% 399.7% -91.8% -100.0% 0.0%
Cur. Ratio 9.40
7.50
4.00
4.13
4.35
1.46
3.19
2.96
2.26
2.37
growth rate -20.2% -46.7% 3.3% 5.3% -66.4% 118.5% -7.2% -23.7% 2.4%
Quick Ratio 8.98
7.29
3.37
3.38
3.51
1.20
2.77
2.34
1.96
2.11
growth rate -18.8% -53.8% 0.3% 3.9% -65.8% 130.8% -15.5% -16.2% 3.8%
Leverage 1.09
1.10
1.15
1.16
1.18
1.57
1.22
1.44
1.53
1.36
growth rate 0.9% 4.6% 0.9% 1.7% 33.1% -22.3% 18.0% 6.3% -5.7%
Balance Sheet Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20 Dec '20 Dec '21
Acct.Receivable 85.10
87.70
95.00
95.90
103.30
138.60
71.00
89.50
91.30
growth rate 3.1% 8.3% 1.0% 7.7% 34.2% -48.8% 26.1% 2.0%
Acct.Payable 23.10
21.10
21.10
22.00
26.00
33.30
21.70
20.50
29.60
growth rate -8.7% 0.0% 4.3% 18.2% 28.1% -34.8% -5.5% 44.4%
Cur.Assets 322.40
283.60
314.50
301.70
327.60
348.60
331.70
389.40
484.80
growth rate -12.0% 10.9% -4.1% 8.6% 6.4% -4.9% 17.4% 24.5%
Total Assets 823.80
766.20
880.50
1,208.90
1,175.30
1,562.70
1,404.60
1,418.80
1,320.70
growth rate -7.0% 14.9% 37.3% -2.8% 33.0% -10.1% 1.0% -6.9%
Cash 64.80
64.10
68.50
102.40
110.90
93.20
163.70
117.00
258.40
growth rate -1.1% 6.9% 49.5% 8.3% -16.0% 75.6% -28.5% 120.9%
Inventory 23.90
25.10
38.30
42.20
34.30
31.40
29.10
27.10
15.30
growth rate 5.0% 52.6% 10.2% -18.7% -8.5% -7.3% -6.9% -43.5%
Cur.Liabilities 80.60
68.70
72.30
217.50
102.20
117.80
147.00
145.90
204.30
growth rate -14.8% 5.2% 200.8% -53.0% 15.3% 24.8% -0.8% 40.0%
Liabilities 104.80
104.10
132.40
440.90
209.20
473.80
486.40
537.80
352.90
growth rate -0.7% 27.2% 233.0% -52.6% 126.5% 2.7% 10.6% -34.4%
LT Debt 99.10
9.30
233.50
224.40
224.80
growth rate -90.6% 2,410.8% -3.9% 0.2%
Equity 719.00
662.10
748.10
768.40
966.10
1,088.90
918.20
881.00
967.80
growth rate -7.9% 13.0% 2.7% 25.7% 12.7% -15.7% -4.1% 9.9%
Common Shares 86.00
83.00
78.00
75.00
73.00
68.00
72.00
0.70
0.70
0.80
0.80
growth rate -3.5% -6.0% -3.9% -2.7% -6.9% 5.9% -99.0% 0.0% 14.3% 0.0%
Cash Flow Statement Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20 Dec '20 Dec '21
Capital Expenditures 14.30
23.90
5.00
6.10
8.40
8.60
10.20
13.20
18.00
growth rate 67.1% -79.1% 22.0% 37.7% 2.4% 18.6% 29.4% 36.4%
Cash From OA 190.20
140.50
166.30
106.20
115.90
83.70
60.70
-26.90
18.20
growth rate -26.1% 18.4% -36.1% 9.1% -27.8% -27.5% -100.0% 100.0%
FCF per Share 1.18
1.29
1.84
1.22
1.92
1.26
1.18
1.06
0.63
-0.47
growth rate 9.3% 42.6% -33.7% 57.4% -34.4% -6.4% -10.2% -40.6% -100.0%
Sale Purchase of Stock 64.80
30.00
94.30
6.00
growth rate -53.7% 214.3% -93.6%
FCF 132.00
162.00
176.00
116.00
161.00
100.00
108.00
75.00
51.00
-40.10
0.20
growth rate 22.7% 8.6% -34.1% 38.8% -37.9% 8.0% -30.6% -32.0% -100.0% 100.0%
Income Statement Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20 Dec '20 Dec '21
Sales 778.20
723.10
740.50
728.70
743.70
851.10
638.60
557.00
690.60
growth rate -7.1% 2.4% -1.6% 2.1% 14.4% -25.0% -12.8% 24.0%
Op.Income 274.40
134.20
153.40
43.20
60.70
7.60
-132.00
-194.80
-126.70
growth rate -51.1% 14.3% -71.8% 40.5% -87.5% -100.0% 0.0% 0.0%
IBT 277.80
134.90
156.00
36.20
120.10
-223.30
-223.30
-283.70
-57.10
growth rate -51.4% 15.6% -76.8% 231.8% -100.0% 0.0% 0.0% 0.0%
Net Income 176.20
80.20
117.20
17.40
133.30
4.60
-199.50
-223.70
-27.20
growth rate -54.5% 46.1% -85.2% 666.1% -96.6% -100.0% 0.0% 0.0%
EPS 1.30
1.77
2.25
1.08
1.60
0.25
1.85
0.06
-2.69
-0.35
growth rate 36.2% 27.1% -52.0% 48.2% -84.4% 640.0% -96.8% -100.0% 0.0%
Gross Profit 669.00
575.70
583.20
557.50
566.50
650.10
452.50
378.80
493.00
growth rate -14.0% 1.3% -4.4% 1.6% 14.8% -30.4% -16.3% 30.2%
R&D 67.50
75.50
70.60
74.40
70.80
85.90
77.20
72.90
81.90
growth rate 11.9% -6.5% 5.4% -4.8% 21.3% -10.1% -5.6% 12.4%

Quarterly Statements

Item Name Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Earnings BIT -18.60
-79.50
17.20
-14.90
-17.80
growth rate 0.0% 100.0% -100.0% 0.0%
Balance Sheet Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Acct.Receivable 94.80
93.60
91.30
101.70
109.80
growth rate -1.3% -2.5% 11.4% 8.0%
Acct.Payable 28.50
15.70
29.60
27.10
21.70
growth rate -44.9% 88.5% -8.5% -19.9%
Cur.Assets 538.90
498.90
484.80
427.40
367.10
growth rate -7.4% -2.8% -11.8% -14.1%
Total Assets 1,360.30
1,335.90
1,320.70
1,255.40
1,210.20
growth rate -1.8% -1.1% -4.9% -3.6%
Cash 118.40
295.20
258.40
165.20
105.20
growth rate 149.3% -12.5% -36.1% -36.3%
Inventory 17.70
18.60
15.30
15.60
15.40
growth rate 5.1% -17.7% 2.0% -1.3%
Cur.Liabilities 271.00
203.20
204.30
166.00
119.70
growth rate -25.0% 0.5% -18.8% -27.9%
Liabilities 457.90
367.40
352.90
305.30
262.80
growth rate -19.8% -4.0% -13.5% -13.9%
LT Debt
growth rate
Equity 902.50
968.60
967.80
950.10
947.40
growth rate 7.3% -0.1% -1.8% -0.3%
Common Shares 0.80
0.80
0.80
0.80
0.80
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Capital Expenditures 4.50
3.00
3.40
6.30
6.70
growth rate -33.3% 13.3% 85.3% 6.4%
Cash From OA -4.40
-39.30
-9.90
-46.50
-50.30
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF -8.90
-42.30
-13.30
-52.80
-57.00
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Sales 189.40
167.30
160.80
164.90
179.30
growth rate -11.7% -3.9% 2.6% 8.7%
Op.Income -18.60
-79.50
17.20
-14.90
-17.80
growth rate 0.0% 100.0% -100.0% 0.0%
IBT -3.80
39.80
-43.50
-26.40
-17.90
growth rate 100.0% -100.0% 0.0% 0.0%
Net Income -4.70
24.60
-7.60
-20.50
-14.10
growth rate 100.0% -100.0% 0.0% 0.0%
Gross Profit 135.70
119.50
115.00
116.90
129.60
growth rate -11.9% -3.8% 1.7% 10.9%
R&D 19.50
18.80
20.50
21.20
20.30
growth rate -3.6% 9.0% 3.4% -4.3%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

F (9.45)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE 36.16 -31.36 70.67
EPS / Growth -6.2% -0.34 -8.2%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 3.4%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 1.8% 1.8%
Future PE 2.00 36.81 36.81
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.